TVTX
Travere Therapeutics
$67.51
+$1.29 (+1.95%)Sep 10, 2026
Key metrics
The numbers that frame TVTX today
- Market cap
- $6.36B
- P/E (TTM)
- -146.4
- EV / FCF
- 445.7
- Gross margin
- 98.6%
- EV / Sales
- 11.6
- ROIC
- -5%
- Div yield
- 0%
- Debt / equity
- 25.2
- 52wk Low
- $22.06
- 52wk High
- $68.59
Growth
Revenue and earnings trend for TVTX
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about TVTX
Is Travere Therapeutics a good buy?
Yes. Travere Therapeutics has strong quality and excellent momentum. Both signals support the setup. Growth looks mixed. The support signal is useful, but not decisive. We think Travere Therapeutics is selling at a high price, which cuts against the buy case.
What is the market capitalization of TVTX?
Travere Therapeutics's market capitalization is $6.36B.
What is the P/E ratio for TVTX stock?
Travere Therapeutics's current P/E ratio is -146.4.
What is the 52-week high for TVTX stock?
The 52-week high for Travere Therapeutics is $68.59. The current close of $67.51 is 1.6% below that high.
What is the 52-week low for TVTX stock?
The 52-week low for Travere Therapeutics is $22.06. The current close of $67.51 is 206.1% above that low.
Does TVTX stock pay dividends?
Travere Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for TVTX?
Travere Therapeutics's Debt / Equity ratio is 25.16.